{"schemaVersion":"411.history/1","type":"revision","id":"7a356aa45f47661c7fd922c3c8232061cffd31c083a9d66fe956193f78787b66","itemId":"medworld411:06d09811ffe00cf8d4b3a28d","legacyId":"06d09811ffe00cf8d4b3a28d","nativeVersion":"history-v1:1","revision":1,"predecessor":null,"observedAt":"2026-11-21T02:50:31.410Z","contentHash":"67084d706cf5d8d0d5147bf24cf12a537cc69ec73f0f89ee00467e87a3a99050","content":{"title":"FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease","url":"http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease","sourceId":"fda","sourceName":"FDA","publishedAt":"2026-11-18T19:13:26.000Z","publishedDate":null,"publishedRaw":"Wed, 18 Nov 2026 14:13:26 EST","updatedRaw":null,"kind":"Official release","deadline":null,"topics":["care"],"section":"policy","classifierVersion":"medworld411.topics/1","vertical":null,"primaryUrl":"http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease","coverageUrl":null},"provenance":{"captureScope":"headline-metadata","publisherEditTimeKnown":false,"importedAt":null,"completeness":"forward-capture-baseline; older native history retained separately"},"release":"0.2.1-vertical.1"}